The startup develops pharmaceutical chemical technology that utilizes protein structure identification and genomics to identify new drug candidates. This approach enhances the efficiency of drug discovery, enabling the development of effective treatments for patients.
Funding
Funding not disclosed
Founders
Product
Problem
The traditional drug discovery process is often slow and inefficient, requiring extensive screening of chemical compounds with limited knowledge of their interaction with target proteins. This can lead to high failure rates in clinical trials and increased costs in bringing new drugs to market.
Solution
MasterMediTech utilizes structure-based drug discovery (SBDD) to accelerate the identification of promising drug candidates. The company focuses on elucidating the 3D structure and function of drug target proteins and employs medicinal chemistry techniques to design molecules that specifically bind to these targets. By integrating genomics, protein structure identification, and in-silico modeling, MasterMediTech enhances the efficiency of drug discovery, potentially reducing the time and cost associated with developing effective treatments. Their approach allows for the rational design of drug candidates with improved efficacy and reduced off-target effects.
Target Audience
MasterMediTech's primary customers are pharmaceutical companies and research institutions seeking to accelerate their drug discovery programs and develop novel therapeutics.
Features
- Protein structure determination using X-ray crystallography and other biophysical methods
- In-silico drug design and molecular docking simulations
- Medicinal chemistry expertise for synthesizing and optimizing drug candidates
- High-throughput screening assays for evaluating compound activity
- Structure-activity relationship (SAR) analysis to guide drug optimization
- Focus on novel drug targets identified through genomics and proteomics